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1. INTRODUCTION {#mgg3792-sec-0005}
===============

Tuberculosis (TB) is a major global health problem and has replaced HIV as the leading cause of death from a single infectious agent in 2016. In 2015, an estimated 10.4 million people developed TB and 1.4 million died from the disease. Tuberculosis is a disease caused by mycobacterium tuberculosis infection. The immunology reaction caused by pathogens during the infection and reproduction of mycobacterium tuberculosis has been studied which leads to the development of vaccine, diagnosis, drug resistance (Horwitz, Lee, Dillon, & Harth, [1995](#mgg3792-bib-0006){ref-type="ref"}; Lindenstrøm et al., [2009](#mgg3792-bib-0010){ref-type="ref"}; Meintjes et al., [2009](#mgg3792-bib-0013){ref-type="ref"}; Vanham et al., [1997](#mgg3792-bib-0016){ref-type="ref"}). Since, the TCR repertoire is a mirror of the human immune response, its characteristics have been widely investigated in infectious and other diseases to study the state of the immune system and the progression of these diseases (Chaudhry, Cairo, Venturi, & Pauza, [2013](#mgg3792-bib-0003){ref-type="ref"}).

The diversity within the TCR repertoire is ensured through somatic recombination of germline‐encoded variable (V), diversity (D), and junctional (J) gene segments. Nucleotide deletions at the coding ends and nucleotide additions at the V(D)J junctions also contribute substantially to the TCR repertoire diversity (Nikolich‐Žugich, Slifka, & Messaoudi, [2004](#mgg3792-bib-0014){ref-type="ref"}). The TCR diversity is a function of the third hypervariable complementary‐determining (CDR3) region, which lies at the intersection between the V, D, J and V, J gene segments within the TCR and TCR chains, respectively. The CDR3 region encodes that part of the TCR which predominantly interacts with antigenic peptide/MHC complexes. Thus, even when T cell clones express the same V/J genes rearrangement, they can be identified by the unique combination of their CDR3 sequences (TCR clonotypes) (Toivonen, Arstila, & Hänninen, [2015](#mgg3792-bib-0015){ref-type="ref"}). Accordingly, the complexity and distribution of TCRs within specific T cell populations will reflect the degree of complexity of the T cell response.

In the present study, we studied the immune repertoire of CD4^+^, CD8^+^ T cells of patients and healthy controls and tissue sample of patients to elucidate the effect of tuberculosis on patients' immune system. The characteristics of diversity and stability, CDR3 length distribution and CDR3 sequences sharing were analyzed. Besides, the usage of TRBJ, TRBV as well as the combination of TRBV/TRBJ were studied. The different repertoire features between tuberculosis patients and controls were then found as future targets for further study.

2. METHODS {#mgg3792-sec-0006}
==========

2.1. Clinical samples {#mgg3792-sec-0007}
---------------------

Tuberculosis tissue samples and blood samples of nine patients and blood samples of nine healthy controls were collected at the Second Clinical Medical College of Jinan University (Shenzhen People\'s Hospital, Guangdong, China). All patients gave written informed consent and the present study was approved by the Medical Ethics Committee of Shenzhen People\'s Hospital.

2.2. DNA extraction and mixing {#mgg3792-sec-0008}
------------------------------

T cell was isolated using superparamagnetic polystyrene beads (Miltenyi) coated with monoclonal antibodies specific for T cells. DNA was prepared from 0.5 to 2 × 10^6^ T cells from each sample (patients and controls), which was sufficient for analyzing the diversity of TCR in the T cell subsets. DNA was extracted from PBMCs using GenFIND DNA (Agencourt, Beckman Coulter, Brea, CA) extraction kits following the manufacturer\'s instructions.

Ten milligrams of tuberculosis tissue was obtained from each patient sample and DNA was extracted using standard methods. Briefly, dewaxing was done using xylene and followed by over‐night proteinase K digestion for tissues. QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany) was further used for DNA extraction following the manufacturer\'s instructions. DNA quality was evaluated by loading on a 0.8% agarose gel electrophoresis and DNA concentration was quantified by Qubit fluorometer. DNA from nine patients\' peripheral blood samples were mixed together by 1:1:1:1:1:1:1:1:1 according to Qubit value, renamed one blood sample. Meanwhile, DNA from nine patients\' tuberculosis tissues and control blood samples were mixed separately in the same way.

2.3. Multiplex‐PCR amplification of TCR‐β CDR3 regions {#mgg3792-sec-0009}
------------------------------------------------------

The human TCR‐β sequences were downloaded from IMGT (<http://www.imgt.org/>). A relative conserved region in frame region 3, upstream of CDR3, was selected for the puta‐ tive forward primer region. A cluster of primers corresponding to the majority of the V gene family sequence was selected. Similarly, reverse primers corresponding to the J gene family were designed. In total, 30 forward primers and 13 reverse primers were used for multiplex PCR to amplify the rearranged TCR‐β CDR3 regions. The reaction mixtures (50 μl total) comprised 2 μl of pooled TCR‐β variable gene (TRBV; 10 μM), 2 μl of pooled TCR‐β joining gene (TRBJ; 10 μM), 25 μl of 2X Qiagen Multiplex PCR Master Mix, 5 μl of 5X Q‐solution, 500 ng of template DNA (10 μl) and 6 μl of H~2~O. The PCR conditions comprised 95 °C for 15 min; followed by 25 cycles of 94 °C for 15 s and 60 °C for 3 min; followed by a final extension for 10 min at 72 °C. The PCR products were purified using AMPure XP beads to remove primer sequences (Beckman Coulter, Inc., Brea, CA, USA). A second round of PCR was performed to add a sequencing index to each sample. In this round, each reaction mixture (50 μl total) consisted of 13.5 μl of H~2~O, 0.5 μl of 2X Q5 DNA polymerase, 10 μl of 5X Q5 buffer, 1 μl of dNTPs (10 mM), 1 μl of P1 (10 μM), 23 μl of DNA, and 1 μl of index (10 μM). The PCR conditions comprised 98 °C for 1 min; followed by 25 cycles of 98 °C for 20 s, 65 °C for 30 s and 72 °C for 30 s; and a final extension for 5 min at 72 °C. The library was separated on an agarose gel, and the target region was isolated and cleaned using QIAquick Gel Extraction kits (Qiagen).

2.4. NGS and data analysis {#mgg3792-sec-0010}
--------------------------

The library was quantitated using the Agilent 2100 Bioanalyzer instrument (Agilent DNA 1,000 reagents) and real‐time quantitative PCR (TaqMan probes) and sequenced by Illumina MiSeq. Briefly, the adaptor reads and low‐quality reads were filtered from the raw data, the clean data was used in further alignments. Subsequently, the clean data was aligned to the human IGH database and analyzed using the online IMGT/HighV‐QUEST tool. The data included V, J assignment, CDR3 length distribution, clustering and other analyses.

3. RESULT {#mgg3792-sec-0011}
=========

3.1. Quality control of all sequencing data {#mgg3792-sec-0012}
-------------------------------------------

Using high‐throughput NGS, we sequenced repertoires CD4^+^ cells, CD8^+^ cells and tissue samples of nine pulmonary tuberculosis patients and nine normal controls. All data passed the QC process with an average Q20 \>99.99%, Q30 \>97.04%. A total sequencing data of total reads number (34094942), immune sequences number (33504380), unknown sequences number (590562), productive sequences number (24345651), nonproductive sequences number (9158729), *In‐frame* sequences number (27088243), *out‐of‐frame* sequences number (6326420), total CDR3 sequences number (23670829), Unique CDR3 nucleotide sequences number (1995707) and Unique CDR3 amino acids sequences number (1723256), details including data from each sample are listed in Table [1](#mgg3792-tbl-0001){ref-type="table"}.

###### 

Sequence quality of CD4^+^, CD8^+^, tissue sample of tuberculosis patients and normal controls

                                       M1‐CD4       M1‐CD8       M1‐Tissue    M2‐CD4       M2‐CD8       M2‐Tissue    M3‐CD4       M3‐CD8       M3‐Tissue    M4‐CD4       M4‐CD8       M4‐Tissue    M5‐CD4       M5‐CD8       M5‐Tissue    M6‐CD4       M6‐CD8       M6‐Tissue    M7‐CD4       M7‐CD8       M7‐Tissue    M8‐CD4       M8‐CD8
  ------------------------------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Total reads number                   582217       459996       677310       903177       575955       335774       889156       643710       573785       1065180      859602       253607       889229       427415       495999       971852       627698       336292       776087       801797       313179       1016582      892231
  Immune sequences number              550596       449546       650380       901272       573975       288998       887379       640989       539209       1062359      857908       195758       886866       424561       458664       970694       625998       286683       774495       799883       256256       1014869      890412
  Unknown sequences numebr             31621        10450        26930        1905         1980         46776        1777         2721         34576        2821         1694         57849        2363         2854         37335        1158         1700         49609        1592         1914         56923        1713         1819
  Productive sequences number          353828       250365       474701       699906       433221       162872       685579       492654       356619       841185       670586       98480        691340       327224       314326       764656       413577       82356        611495       700658       102129       810266       738949
  Nonproductive sequences number       196768       199181       175679       201366       140754       126126       201800       148335       182590       221174       187322       97278        195526       97337        144338       206038       212421       204327       163000       99225        154127       204603       151463
  In‐frame sequences number            377268       289584       502949       746867       461590       187810       731817       527307       377228       900754       717545       110971       738864       344971       323396       816839       435942       88467        654902       743398       106464       861847       783627
  Out‐of_frame sequences number        163201       158365       145359       153605       111898       94557        154889       113184       159463       160716       139871       81018        147303       78997        129220       153394       189766       178497       119143       55925        143195       152559       106321
  Total CDR3 sequences number          327059       233666       441542       677038       420582       153780       674805       484420       347379       817310       622440       84721        680369       321140       304849       752939       407462       46143        602093       691660       75485        798558       728731
  Unique CDR3 nt sequences number      14090        12645        20153        60934        26558        16661        65880        32174        18011        65934        51955        11956        51934        18470        6677         123828       18610        4807         69335        22394        4851         74991        48370
  Unique CDR3 aa sequences number      11656        10237        17021        51459        21942        15302        56729        27010        15661        54642        43502        11351        43869        15337        5265         112096       15068        4416         60466        18165        4371         63893        40937
  Highly expressing clone number all   41           38           53           2            18           28           5            16           48           0            11           21           4            20           26           2            24           40           1            11           30           0            8
  Highly expressing clone ratio all    0.68255575   0.52631534   0.63128989   0.02411238   0.31779772   0.71275849   0.05190685   0.34143305   0.68128471   0            0.15724086   0.6742012    0.05387518   0.50208009   0.90383436   0.05658493   0.4683357    0.7194374    0.00541112   0.6621259    0.78404981   0            0.30130597
  Shannon entropy all                  0.39719054   0.45082821   0.41825992   0.68833416   0.54280623   0.43039658   0.67979693   0.51286718   0.40022774   0.66933299   0.63017905   0.41873046   0.59746329   0.42595744   0.26421886   0.76166681   0.45595582   0.45273164   0.72728526   0.30304497   0.37782448   0.69998144   0.53009339

                                       M8‐Tissue    M9‐CD4       M9‐CD8       M9‐Tissue    N1‐CD4       N1‐CD8       N2‐CD4       N2‐CD8       N3‐CD4       N3‐CD8       N4‐CD4       N4‐CD8       N5‐CD4       N5‐CD8       N6‐CD4       N6‐CD8       N7‐CD4       N7‐CD8       N8‐CD4       N8‐CD8       N9‐CD4       N9‐CD8       Sum
  ------------------------------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Total reads number                   345124       920454       612229       644546       734122       1015119      487365       1090624      948621       1738242      609,319      790,880      691,014      675,691      528,099      811,278      1,360,226    1,129,827    1,023,104    569,829      907,554      1,093,845    34,094,942
  Immune sequences number              263278       918689       609826       615559       731341       1005773      486477       1089108      945180       1733207      598,136      778,657      689,656      671,243      526,754      806,631      1,355,308    1,122,850    1,015,052    558,523      905,671      1,089,711    33,504,380
  Unknown sequences numebr             81846        1765         2403         28987        2781         9346         888          1516         3441         5035         11,183       12,223       1,358        4,448        1,345        4,647        4,918        6,977        8,052        11,306       1883         4,134        590,562
  Productive sequences number          29271        740140       365631       448227       572690       632787       392543       748995       771280       478426       461,805      655,143      543,636      540,734      421,049      459,848      1,144,179    892,295      785,584      447,734      751,448      985,234      24,345,651
  Nonproductive sequences number       234007       178549       244195       167332       158651       372986       93934        340113       173900       1254781      136,331      123,514      146,020      130,509      105,705      346,783      211,129      230,555      229,468      110,789      154,223      104,477      9,158,729
  In‐frame sequences number            31239        791611       389714       478815       611479       674818       419284       803236       826442       1639631      491,438      700,926      581,739      579,260      447,370      493,172      1,214,667    940,753      837,153      476,306      801,996      1,026,787    27,088,243
  Out‐of_frame sequences number        223550       126583       219578       132408       119590       330324       67051        285651       118315       93141        105,943      76,022       107,717      91,455       79,183       312,915      140,233      181,609      177,241      81,689       103,394      62,382       6,326,420
  Total CDR3 sequences number          4069         729342       359173       437648       562036       620952       386428       737296       758769       471122       452,601      637,937      526,892      524,563      414,324      451,689      1,122,330    875,610      772,434      440,452      733,117      957,874      23,670,829
  Unique CDR3 nt sequences number      2560         59322        22290        23141        58045        59010        47160        63725        123378       36185        27,333       27,072       117,546      33,206       87,434       39,496       52,585       27,685       57,173       28,979       127,052      34,112       1,995,707
  Unique CDR3 aa sequences number      2529         49316        18368        20092        49690        51530        41236        55749        110754       30566        22,684       21,878       108,153      27,439       80,135       33,719       42,691       21,744       48,099       23,821       115,038      27,630       1,723,256
  Highly expressing clone number all   14           0            7            47           0            5            3            10           4            14           15           10           4            12           2            10           7            16           3            12           3            10           655
  Highly expressing clone ratio all    0.16515114   0            0.24276881   0.72208259   0            0.09839569   0.03277972   0.33245806   0.04359034   0.21227835   0.24436535   0.49173821   0.07930088   0.31473055   0.01548547   0.24206478   0.41441287   0.64089949   0.10992525   0.21462044   0.06475638   0.61016585   14.5499069
  Shannon entropy all                  0.8638929    0.66876197   0.52750687   0.40509952   0.67976672   0.59714855   0.7164873    0.55144703   0.74832534   0.57724095   0.49459581   0.37677137   0.78381492   0.52494136   0.79603452   0.58333764   0.44022788   0.34205038   0.5889533    0.56018664   0.75464691   0.33202264   24.7484339
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3.2. Diversity and stability of repertoire in different groups {#mgg3792-sec-0013}
--------------------------------------------------------------

The distribution characteristics of the sequences and clone expansion were analyzed firstly. In the current study, the expression level of certain CDR3 clones higher than 0.5% of total clones was defined as high expansion clones (HECs). In tuberculosis patients, the HEC number was higher in the tissue group than that in the CD8 group or the CD4 group, while the comparison between the CD4 and CD8 groups showed no statistical difference. In the control groups, the HEC number in the CD8 group was significantly higher than that of the CD4 group (Figure [1](#mgg3792-fig-0001){ref-type="fig"}a). In the comparison of HEC ratio, tuberculosis patients' tissue group showed higher ratio than CD8 or CD4 groups, and that of CD8 group was higher than in CD4 group. In consistent with HEC number, the HEC ratio of CD8 group was higher than in CD4 group in control group (Figure [1](#mgg3792-fig-0001){ref-type="fig"}b). The Shannon entropy measures multiplex of the immune system. It ranges from 0 to 1, "1" represents the most diversity and "0" represents the least diversity of immune system. In tuberculosis patients, Shannon entropy in CD4 was higher than CD8 or tissues, while tissue group showed the lowest Shannon entropy, although entropy of CD8 was not statistically higher than tissue group. In controls, Shannon entropy in CD4 was also higher than that of CD8 group (Figure [1](#mgg3792-fig-0001){ref-type="fig"}c).

![CDR3 clones in patients and controls. (a) HEC number comparison of patients and controls. MCD4: CD4^+^ cells of tuberculosis patients, MCD8: CD8^+^ cells of patients, MTis: tissue samples of patients. NCD4: CD4^+^ cells of controls, NCD8: CD8^+^ cells of controls. (b) HEC ratio analysis of patients and controls. (c) Shannon entropy of patients and controls](MGG3-7-e00792-g001){#mgg3792-fig-0001}

The Gini coefficient was then calculated to further understand the stability of tuberculosis patients' immune system. In patients, Gini coefficient in CD8 was higher than in CD4 group, while other comparisons showed no significant change. In controls, Gini coefficient in CD8 group was higher than that of CD4 group (Figure [2](#mgg3792-fig-0002){ref-type="fig"}).

![Gini coefficient of patients and controls. (a) Comparison of CD4^+^ cell group, CD8^+^ cell group and tissue group of patients. (b) Comparison of CD4^+^ cell group in patients and CD4^+^ cell group in controls. (c) Comparison of CD8^+^ cell in patient group and CD8^+^ group in control. (d) Comparison of control CD8^+^ cell group and CD4^+^ cell group](MGG3-7-e00792-g002){#mgg3792-fig-0002}

3.3. CDR3 length distribution mode analysis {#mgg3792-sec-0014}
-------------------------------------------

In addition, we made further analysis of CDR3 length distribution in all samples and the differences between groups. We first fit the Gaussian distribution of each sample and compared the R^2^value between each sample and each group. The R^2^ value ranged from 0 to 1, suggesting the worst fitted Gaussian distribution to the best fitted distribution. According to the R^2^ value, the length distribution of all samples was fitted to Gaussian distribution, although no statistical significance was found for comparing between groups, as shown in Figures [3](#mgg3792-fig-0003){ref-type="fig"} and [4](#mgg3792-fig-0004){ref-type="fig"}.

![Gaussian distribution of *R* ^2^value in all samples. The X‐axis depicts each CDR3 length (1--30), and the Y‐axis depicts the total percentage of each length](MGG3-7-e00792-g003){#mgg3792-fig-0003}

![Gaussian distribution of *R* ^2^value between groups. (a) Comparison among CD4^+^, CD8^+^ and tissue sample groups in patients. (b) Comparison among CD4^+^ and CD8^+^ cell groups in controls](MGG3-7-e00792-g004){#mgg3792-fig-0004}

The nucleotides and amino acids length of all samples were analyzed. As shown in Figures [3](#mgg3792-fig-0003){ref-type="fig"} and [5](#mgg3792-fig-0005){ref-type="fig"}, the length distribution of CDR3 sequences ranged from 1--30 nucleotides and followed a Gaussian distribution. Besides, both nucleotides and amino acids length distribution of the high expression clones showed a significant difference between the control and tuberculosis patients. In both tuberculosis patients and controls, the amino acids sequence ranged from 1 to 30 amino acids and the highest percentage for both was 13 amino acid sequences. The CDR3 length of CD4, CD8 and tissue groups was analyzed, and it was observed that all presented with a similar pattern with the whole patient group. However, we found that the amino acid length of 1, 2, 5, 25, 27, 28, 29 were absent in more than seven samples in tissue group (*n* = 9), which is rare in CD4 and CD8 groups. In healthy controls, the amino acids sequence also ranged from 1 to 30 amino acids and the highest percentage was 13 amino acid sequences. For the distribution of CDR3 length, there were no statistically significant differences as has been found between groups. All samples showed a Gaussian distribution, the highest percentage centralized at 13 amino acids. Besides, CDR3 length of tissue group showed more skewed as length 1, 2, 5, 25, 27, 28, 29 were absent in most of tissue sample (Figure [6](#mgg3792-fig-0006){ref-type="fig"}).

![CDR3 length distribution in all samples. X‐axis represents length distribution, Y‐axis depicts the percentage of sequences of the corresponding length](MGG3-7-e00792-g005){#mgg3792-fig-0005}

![CDR3 expression status in all samples. X‐axis is sample ID and M1‐M9 represents tuberculosis patient number 1‐9. N1‐N9 represent control sample number 1‐9. CD4, CD8 and Tissue mean different sample types. Y‐axis is the percentage of CDR3 clones in each sample\'s different sequences. Red dots mean highly expressing clones (≥0.5%) and black dots represent normal expressing clones (\<0.5%). (a) CDR3 clones (b) amino acid of CDR3 clones](MGG3-7-e00792-g006){#mgg3792-fig-0006}

3.4. CDR3 sequence sharing modes analysis {#mgg3792-sec-0015}
-----------------------------------------

Different individuals sharing an identical TCR sequence corresponding to the same antigenic epitope, termed public T cell response, were observed in a variety of immune responses, including tumorigenesis, autoimmunity, and viral infections. So, we counted the public T cell clones in each group based on the nucleotide and amino acid sequences of CDR3 (Li, Ye, Ji, & Han, [2012](#mgg3792-bib-0009){ref-type="ref"}). In order to understand the immunological reaction to the common tuberculosis pathogens, the sharing pattern of CDR3 sequence were analyzed between patients. According to the sequence data, there were 586,248 nucleotide sequences and 504,126 amino acids sequences in CD4 group of patients, and 697,706 nucleotide sequences and 618,480 amino acids sequences in CD4 group of controls. There were 253,466 nucleotide sequences and 210,566 amino acids sequences in CD8 group of patients, 349,470 nucleotide sequences and 294,076 amino acids sequences in CD8 group of control. In addition, in tissue samples of patients, we obtained 108,817 nucleotide sequences and 96,008 amino acids sequences.

To elucidate the characteristics of sharing sequences, we compared the amino acid sequences and nucleotide sequences of highly expressed clones which were expressed in more than 0.5% in either patient group or control group (Figure [7](#mgg3792-fig-0007){ref-type="fig"}). In patient group, eight amino acid sequences and eight nucleotide sequences were shared in all samples from CD4, CD8 and tissue groups. However, 35 amino acid sequences and 33 nucleotide sequences were shared in CD4 and CD8 samples of patient, while there were 61 amino acid sequences and 61 nucleotide sequences that were shared in CD4 and CD8 samples of control. No amino acid or nucleotide sequences were shared in CD4 and CD8 in both patients and controls. All shared sequences are displayed in Table [2](#mgg3792-tbl-0002){ref-type="table"}.

![Top 60 expressing clones in all samples. Red rectangle: expression percentage ≥0.5%, green rectangle: expression percentage \>0, gray rectangle = 0. (a) Nucleotide sequences of top 60 expressed clones in CD4^+^ and CD8^+^ group of patients. (b) Nucleotide sequences of top 60 expressed clones in CD4^+^, CD8^+^ and tissue group of patients. (c) Amino acids sequences of top 60 expressed clones in CD4^+^ and CD8^+^ group of patients. (d) Nucleotide sequences of top 60 expressed clones in CD4^+^ and CD8^+^ group of controls.](MGG3-7-e00792-g007){#mgg3792-fig-0007}

###### 

Shared sequence in all patient samples, in CD4^+^ and CD8^+^ cells of patients, in CD4^+^ and CD8^+^ cells of controls

  Group                              Shared sequences (NT)                                          Shared sequences (AA)
  ---------------------------------- -------------------------------------------------------------- -----------------------
  Shared sequences in all patients   GCCTGGAGCTTCGGGAGAACTGAAGCTTTC                                 AWSFGRTEAF
                                     GCCAGCATGGGTAACACCGGGGAGCTGTTT                                 ASMGNTGELF
                                     GCCAGCAGTTACTCTGGGACAGGGGGCGAGCAGTAC                           ASSYSGTGGEQY
                                     GCCAGCAGTGAGAGCGGGGACTCCTCCTACGAGCAGTAC                        ASSESGDSSYEQY
                                     GCCTGGGTAAGGGACTACCCGTCGGACGAGCAGTAC                           AWVRDYPSDEQY
                                     GCCTGGAGTCCCCGTACGAAGTTAGCTTTC                                 AWSPRTKLAF
                                     GCCTGGGTTAGCGGGAGCACGGACACCGGGGAGCTGTTT                        AWVSGSTDTGELF
                                     GCCAGCAGTGTCGGGACTCTCATCAATGAGCAGTTC                           ASSVGTLINEQF
  CD4 and CD8 of patient             GCCTGGAGCTTCGGGAGAACTGAAGCTTTC                                 AWSFGRTEAF
                                     GCCAGCATGGGTAACACCGGGGAGCTGTTT                                 ASMGNTGELF
                                     GCCAGCAGTTACTCTGGGACAGGGGGCGAGCAGTAC                           ASSYSGTGGEQY
                                     GCCAGCAGAGATATTGACAGGGAAGACAATGAGCAGTTC                        ASRDIDREDNEQF
                                     GCCAGCAGTGAGAGCGGGGACTCCTCCTACGAGCAGTAC                        ASSESGDSSYEQY
                                     GCCTGGAGTGATGTGGGGGAGACCCAGTAC                                 AWSDVGETQY
                                     GCCAGCAGCCAAGAGGGTAGCGGGAGTCAGGAGACCCAGTAC                     ASSQEGSGSQETQY
                                     GCCAGCAGTTACTCGGACAGGAGCTCCTACGAGCAGTAC                        ASSYSDRSSYEQY
                                     GCCAGCAGATTTGACAGGGACCATTCACCCCTCCAC                           ASRFDRDHSPLH
                                     GCCAGCAGTTACAGGCCGAACACCGGGGAGCTGTTT                           ASSYRPNTGELF
                                     GCCAGCAGTTGGGGGGAGACCCAGTAC                                    ASSWGETQY
                                     GCCTGGGTTAGCGGGAGCACGGACACCGGGGAGCTGTTT                        AWVSGSTDTGELF
                                     GCCAGCAGTTACAGGTCAGGATCCTACGAGCAGTAC                           ASSYRSGSYEQY
                                     GCCAGCGCAACCGGGACAGGGGTTCAAGAGACCCAGTAC                        ASATGTGVQETQY
                                     GCCTGGGTAAGGGACTACCCGTCGGACGAGCAGTAC                           AWVRDYPSDEQY
                                     GCCTGGAGAACTGGGAACTATGGCTACACC                                 AWRTGNYGYT
                                     GCCAGCAGGCCAAGGGGCGGGGGAGGTTTCGGGGAGCTGTTT                     ASRPRGGGGFGELF
                                     GCCTGGAGTGGCAGGGTCTTGTGGGACACCGGGGAGCTGTTT                     ASSSEQAVREKLF
                                     GCCAGCAGCTCGGAACAGGCAGTACGGGAAAAACTGTTT                        AWSGRVLWDTGELF
                                     GCCAGCAGTTTATCGTGGGGAGAGACCCAGTAC                              ASSLSWGETQY
                                     GCCAGCAGTGTGGGGAGGAACACTGAAGCTTTC                              ASSVGRNTEAF
                                     GCCAGCAGCTTGGAGCAGACGGCACGCAGCAATGAGCAGTTC                     ASSLGWGTGSTNEKLF
                                     GCCTGGAGTTTGGGGGTGTCTAACTATGGCTACACC                           ASSLEQTARSNEQF
                                     GCCTGGAGCGGACAGGGCTACGAGCAGTAC                                 AWSLGVSNYGYT
                                     GCCAGCAGGCGGGGGTGGGACACCGGGGAGCTGTTT                           AWSGQGYEQY
                                     GCCTGGAACCGGGACACTGAAGCTTTC                                    ASRRGWDTGELF
                                     GCCTGGAGTCCCCGTACGAAGTTAGCTTTC                                 AWNRDTEAF
                                     GCCAGCAGCTTAGAGGGGGGGAGTTTTAATCATGAAAAACTGTTT                  AWSPRTKLAF
                                     GCCTGGACTGAGTTCGGAGGCACCGGGGAGCTGTTT                           ASSLEGGSFNHEKLF
                                     GCCAGCAGTTTACGTCCCGTTGAGGTCAATGAGCAGTTC                        AWTEFGGTGELF
                                     GCCTGGAGTCTCCGGACAGGGTTCTGGGGGCAGGGCGCGGGTACGGGAGAGACCCAGTAC   ASSLEQGARSDEQF
                                     GCCAGCAGTTACGGGCGGGAGAAGTCCGGGGAGCTGTTT                        ASSLRPVEVNEQF
                                     GCCAGCAGTTTCTCTCTAAACACCGGGGAGCTGTTT                           AWSLRTGFWGQGAGTGETQY
                                                                                                    ASSYGREKSGELF
                                                                                                    ASSFSLNTGELF
  CD4 and CD8 of controls            GCCTGGAGTGTAGGGACAGGGGACTCCTACGAGCAGTAC                        AWSVGTGDSYEQY
                                     AGTGCTAGAGATGCGAGGGTTCAAGACACCGGGGAGCTGTTT                     SARDARVQDTGELF
                                     GCCTGGAGTCGAGTGATGAACACTGAAGCTTTC                              AWSRVMNTEAF
                                     GCCTGGAGGATAGGGAGTCTAGTAGGCGAGCAGTAC                           AWRIGSLVGEQY
                                     AGTGCTCATGCCGGACAGGGAGAAACAGATACGCAGTAT                        SAHAGQGETDTQY
                                     AGTGCTAGACCTTACGACAGGGGGACCACCGGGGAGCTGTTT                     SARPYDRGTTGELF
                                     AGTGCTAGTCGGGATTGGGACGATACTAATGAAAAACTGTTT                     SASRDWDDTNEKLF
                                     GCCAGCAGCTTGGAACAGGGGGCTCGCACAGATACGCAGTAT                     ASSLEQGARTDTQY
                                     GCCTGGAGGGGAAAGGGTTTCACTGAAGCTTTC                              AWSVLAGETGELF
                                     GCCTGGAGCGTCCTAGCGGGAGAAACCGGGGAGCTGTTT                        AWRGKGFTEAF
                                     GCCAGCAGTTACAGGGGCCTATTGACTGAAGCTTTC                           ASSYRGLLTEAF
                                     GCCAGCACTCCGGACAGGGGACGAGGCTACACC                              ASTPDRGRGYT
                                     GCCAGCAGTTTAAAGGGACCTTACACTGAAGCTTTC                           ASSLKGPYTEAF
                                     GCCAGCAGTTACTCAGGCGAGCGGCCCTACAATGAGCAGTTC                     ASSYSGERPYNEQF
                                     GCCTGGAGTGTGACAGCCTACGAGCAGTAC                                 AWSVTAYEQY
                                     GCCTGGAGTGTACAGGTCGGGTTTGGAGAGACCCAGTAC                        AWSVQVGFGETQY
                                     GCCAGCAGTTACAAGGGAAACAACTATGGCTACACC                           ASSYKGNNYGYT
                                     GCCTGGGGGGCGGAGACCTACGAGCAGTAC                                 AWGAETYEQY
                                     GCTAGTGCCACAGACTCCTACAATGAGCAGTTC                              ASATDSYNEQF
                                     GCCAGCAGTTACGGGGCTACTGAAGCTTTC                                 ASSYGATEAF
                                     GCCAGCAGTTTAGCACCCACCTCCTACAATGAGCAGTTC                        ASSLAPTSYNEQF
                                     GCCAGCAGTTGGAGGGTAAGGAAGCCTGGAAACACCATATAT                     ASSWRVRKPGNTIY
                                     GCCAGCAGCTTGGTGATCGGGGATCGCCCCTACGAGCAGTAC                     ASSLVIGDRPYEQY
                                     GCCAGCAGCCAAGGAAGACAGGGCTACGAGCAGTAC                           ASSQGRQGYEQY
                                     GCCAGCAGTTACAGTTTTAGCAATCAGCCCCAGCAT                           ASSYSFSNQPQH
                                     GCCAGCAGTTCCCCCACCTACGAGCAGTAC                                 ASSSPTYEQY
                                     AGTGCCGAGGACAGTTCGTTGGGGAGCAATCAGCCCCAGCAT                     SAEDSSLGSNQPQH
                                     GCCAGCAGTCCGACAGGGGGCGGGGAGTATGGCTACACC                        ASSPTGGGEYGYT
                                     GCCTGGGAACCCCCGACTAGCGGGGGGTACGAGCAGTAC                        AWEPPTSGGYEQY
                                     GCCAGTAGCGGGAGTAACACCGGGGAGCTGTTT                              ASSGSNTGELF
                                     GCCTGGAGGAGTTTACGGGGCGTAAGGTCCTACGAGCAGTAC                     AWRSLRGVRSYEQY
                                     GCCAGCAGGACTAGCTCCACGAACACCGGGGAGCTGTTT                        ASRTSSTNTGELF
                                     GCCAGCAGTTTAGATGAGGGGGGGCCGAACACTGAAGCTTTC                     ASSLDEGGPNTEAF
                                     GCCTGGAGCTCGGGAGGCCTCAATCAGCCCCAGCAT                           AWSSGGLNQPQH
                                     GCCAGCGGGAGGACGGGACAGGGCTACGAGCAGTAC                           ASGRTGQGYEQY
                                     GCCTGGACCGAGGGACCGAACACCGGGGAGCTGTTT                           AWTEGPNTGELF
                                     AGTGCTAGAGTTTCTTCGGGTGGAGGGATGAACACTGAAGCTTTC                  SARVSSGGGMNTEAF
                                     GCCAGCAGTTCTGGGACTAGCAGTTACAATGAGCAGTTC                        ASSSGTSSYNEQF
                                     GCCTGGAGACAGGCGAACACTGAAGCTTTC                                 ASSLGTDRSTEAF
                                     GCCAGCAGCTTGGGGACAGATCGCTCGACTGAAGCTTTC                        AWRQANTEAF
                                     GCCAGCAGCCTCGTGGGCGACAGACACTACTCTGGAAACACCATATAT               ASSLVGDRHYSGNTIY
                                     GCCAGCAGCTCGCCCTACAGGGGCGGCCACTCTGGGGCCAACGTCCTGACT            ASSSPYRGGHSGANVLT
                                     GCCAGCAGTGCAGGGTCCACTGAAGCTTTC                                 ASSAGSTEAF
                                     GCCTGGAGTGTTGGAGGGAGGTTTGAAGATACGCAGTAT                        AWSVGGRFEDTQY
                                     GCCAGCAGCCAAGATCTCGGGGTTTCGTCAGGGGGAGGGGTGGGGGAGCAGTAC         ASSQDLGVSSGGGVGEQY
                                     GCCTGGAGTTTAAGCGGGAGGGCCGGCGAGCAGTAC                           AWSLSGRAGEQY
                                     GCCTGGAGTGTACCAGGGGAGGACACCGGGGAGCTGTTT                        AWSVPGEDTGELF
                                     GCCAGCAGTTTAGTCCCAGGGGGAAATGGCTACACC                           ASSLVPGGNGYT
                                     GCCTGGAGTGGTCCCCCAACTAATGAAAAACTGTTT                           AWSGPPTNEKLF
                                     GCCAGCAGTTGGGGGGGGACTCCCTACGAGCAGTAC                           ASSWGGTPYEQY
                                     GCCAGCAGTCGCGGGGCAGGGGGTTACAATGAGCAGTTC                        ASSRGAGGYNEQF
                                     GCCTGGAGTGAGGGGGTCGGAAACACCATATAT                              AWSEGVGNTIY
                                     GCCTGGAGTTCGACAGGGTCTAGCACAGATACGCAGTAT                        AWSSTGSSTDTQY
                                     GCCAGCAGTTATGGACAGTTCTCCATTCAGTAC                              ASSYGQFSIQY
                                     GCCAGCAGCTCCTACTTCCGACAGGGCCCCCAAGAGACCCAGTAC                  ASSSYFRQGPQETQY
                                     GCCAGCAGCAGTCATGGGGGGCGAGAGGACGAGCAGTAC                        ASSSHGGREDEQY
                                     GCCTGGGCCGACAGCTCTGGAAACACCATATAT                              AWADSSGNTIY
                                     GCCTGGAGGGACGGGGGGCGGGACACCGGGGAGCTGTTT                        AWRDGGRDTGELF
                                     GCCAGCAGCTCGGGGACAGGGAGAGGGGATGGCTACACC                        ASSSGTGRGDGYT
                                     GCCAGCAGCTTGGGCCCATTAGGGGCGGCTAACTATGGCTACACC                  ASSLGPLGAANYGYT
                                     GCCAGCAGCTTGGGCCTACTAGCAGATACGCAGTAT                           ASSLGLLADTQY
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3.5. Significance of TRBV and TRBJ usage in patients and controls {#mgg3792-sec-0016}
-----------------------------------------------------------------

In addition, to elucidate the potential specific immune reaction to tuberculosis, usage of TRBV and TRBJ was analyzed in all groups.

In patients, TRBV13 and TRBV6‐4 were significantly highly expressed in CD8 group than in CD4 group, on the contrary TRBV10‐3, TRBV20‐1, TRBV3‐1, TRBV5‐1, TRBV5‐4, TRBV6‐6 showed significantly lower expression in CD8 group than in CD4 group. The expression of TRBV10‐3, TRBV18, TRBV24‐1, RBV24/OR9‐2, TRBV28, TRBV3‐1, TRBV5‐5, TRBV5‐8, TRBV6‐1, TRBV6‐6, TRBV6‐7, TRBV6‐9, TRBV7‐6, TRBV7‐7 was also higher in CD4 than in tissue group. TRBV10‐3, TRBV13, TRBV27, TRBV28, TRBV6‐2, TRBV6‐3, TRBV6‐4, TRBV6‐7, TRBV6‐9 were highly expressed in CD8 samples than in tissues while TRBV20‐1, TRBV5‐1 showed lower expression in CD8 samples than in tissue samples. In controls, TRBV11‐1, TRBV14, TRBV3‐1, TRBV6‐6, TRBV7‐2 and TRBV7‐7 exhibited significant higher expression in CD4 group than in CD8 group, while TRBV27, TRBV7‐6, TRBV9 all showed lower expression in CD4 group than in CD8 group. Moreover, TRBV3‐1 and TRBV4‐1, TRBV5‐8 and TRBV7‐3 in controls' CD4 group showed statistically lower expression than that of in patients. TRBV11‐1 and TRBV7‐2 exhibited higher expression in patients' CD8 group than that of control\'s (Figure [8](#mgg3792-fig-0008){ref-type="fig"}).

![Comparison of TRBV gene usage in groups. X‐axis represents the genes of TRBV. Y‐axis represents the expressing percentage of corresponding gene: (a) CD4^+^ cell and CD8^+^ cell groups in patients. (b) CD4^+^ cell and tissue groups in patients. (c) CD8^+^ cell and tissue groups in patients. (d) CD4^+^ cell and CD8^+^ cell groups in controls. (e) CD4^+^ cell group of patients and CD4^+^ cell group of controls. (f) CD8^+^ cell group of patients and CD8^+^ cell group of controls](MGG3-7-e00792-g008){#mgg3792-fig-0008}

In patients, TRBJ1‐3, TRBJ2‐6 were significantly highly expressed in CD8 group than in CD4 group, on the contrary TRBJ1‐5 showed lower expression in CD8 group than in CD4 group. The expression of TRBJ1‐3, TRBJ1‐5, TRBJ2‐4, TRBJ2‐5 was also higher in CD4 than in tissue group, and TRBJ2‐7 exhibited lower expression in CD4 than in tissue group. TRBJ1‐2 showed lower expression and TRBJ2‐5 presented higher expression in CD8 group than in tissue group respectively. In controls, TRBJ1‐2, TRBJ1‐6, TRBJ2‐4, TRBJ2‐5 exhibited significant higher expression in CD4 group than in CD8 group. Besides, TRBJ1‐6 and TRBJ2‐7 in controls' CD4 group showed statistical higher expression than that of patients. While TRBJ1‐3 in controls' CD4 group showed lower expression than patients' expression. TRBJ2‐5 exhibited higher expression in patients' CD8 group than that of control\'s (Figure [9](#mgg3792-fig-0009){ref-type="fig"}). Top 20 genes in each group are shown in Figure [10](#mgg3792-fig-0010){ref-type="fig"}.

![Comparison of TRBJ gene usage in groups. X‐axis represents the genes of TRBJ. Y‐axis depicts expressing percentage of corresponding gene. (a) CD4^+^ cell and CD8^+^ cell groups in patients. (b) CD4^+^ cell and tissue groups in patients. (c) CD8^+^ cell and tissue groups in patients. (d) CD4^+^ cell and CD8^+^ cell groups in controls. (e) CD4^+^ cell group of patients and CD4^+^ cell group of controls. (f) CD8^+^ cell group of patients and CD8^+^ cell group of controls](MGG3-7-e00792-g009){#mgg3792-fig-0009}

![Top 20 used TRBV genes in each group. X‐axis is sample ID, N1‐N9 represent control sample number 1--9. CD4, CD8 and Tissue mean different sample types. Y‐axis represents the frequencies of corresponding reads. (a) Top 20 used TRBV genes in CD4^+^ cell group of patients. (b) Top 20 used TRBV genes in CD8^+^ cell group of patients. (c) Top 20 used TRBV genes in tissue group of patients. (d) Top 20 used TRBV genes in CD4^+^ cell group of controls. (e) Top 20 used TRBV genes in CD8^+^ cell group of controls. (f) Top 20 used TRBV genes in all sample groups](MGG3-7-e00792-g010){#mgg3792-fig-0010}

Additionally, we combined the expression data of all samples on TRBV or TRBJ to understand the correlation between the expression in the samples. The heatmaps are shown in Figure [11](#mgg3792-fig-0011){ref-type="fig"}.

![Heatmap of TRBV and TRBJ usage in all samples. Heatmap of gene usage in comparison of all samples for (a) TRBV (b) TRBJ](MGG3-7-e00792-g011){#mgg3792-fig-0011}

3.6. Combination of usage of TRBV and TRBJ in tuberculosis patients and control samples {#mgg3792-sec-0017}
---------------------------------------------------------------------------------------

TRBV/TRBJ combination was an important source of CDR3 sequence diversification. Within all TRBV/TRBJ combinations, we first counted the highly expressed which represent more than 0.5% of all combinations in each group. For CD4 group in controls, there were six TRBV/TRBJ combinations which were used more than 0.5%, and the number is 22 in CD8 group in controls. In the tuberculosis patient group, there were also six TRBV/TRBJ combinations which were used more than 0.5% in CD4 group, and 21 high expression TRBV/TRBJ in CD8 group, and 32 high expression TRBV/TRBJ in tissue group (Table [3](#mgg3792-tbl-0003){ref-type="table"}).

###### 

Combination of usage of TRBV and TRBJ in tuberculosis patients and control samples

  V_type     J_type    count     individual   Percent
  ---------- --------- --------- ------------ ------------
  TRBV30     TRBJ2‐7   243,097   N7‐CD4       21.6600287
  TRBV20‐1   TRBJ2‐2   233,941   N7‐CD4       20.8442259
  TRBV30     TRBJ2‐7   77,626    N4‐CD4       17.1510889
  TRBV30     TRBJ2‐5   51,206    N5‐CD4       9.71850019
  TRBV6‐1    TRBJ1‐2   66,181    N8‐CD4       8.56785175
  TRBV6‐6    TRBJ1‐2   49,082    N9‐CD4       6.69497502
  TRBV30     TRBJ2‐7   285,440   N4‐CD8       44.7442302
  TRBV20‐1   TRBJ2‐2   361,501   N9‐CD8       37.7399324
  TRBV30     TRBJ1‐1   164,581   N2‐CD8       22.3222424
  TRBV20‐1   TRBJ2‐3   190,384   N7‐CD8       21.7430134
  TRBV20‐1   TRBJ1‐4   178,703   N9‐CD8       18.6562116
  TRBV30     TRBJ1‐1   62,806    N6‐CD8       13.9046999
  TRBV30     TRBJ2‐2   108,417   N7‐CD8       12.3818823
  TRBV30     TRBJ2‐7   80,921    N2‐CD8       10.9753749
  TRBV5‐1    TRBJ2‐3   87,949    N7‐CD8       10.044312
  TRBV30     TRBJ2‐7   48,860    N5‐CD8       9.31441981
  TRBV6‐5    TRBJ1‐1   48,079    N5‐CD8       9.16553398
  TRBV12‐3   TRBJ1‐1   73,219    N7‐CD8       8.36205617
  TRBV6‐5    TRBJ2‐1   41,462    N5‐CD8       7.90410303
  TRBV12‐3   TRBJ2‐1   32,958    N8‐CD8       7.4827677
  TRBV30     TRBJ2‐7   63,002    N7‐CD8       7.19521248
  TRBV30     TRBJ1‐1   42,289    N1‐CD8       6.81034927
  TRBV30     TRBJ2‐7   29,944    N6‐CD8       6.6293401
  TRBV4‐3    TRBJ2‐7   36,285    N1‐CD8       5.84344684
  TRBV12‐3   TRBJ1‐2   25,505    N8‐CD8       5.79064234
  TRBV6‐5    TRBJ1‐1   25,641    N6‐CD8       5.67669348
  TRBV12‐5   TRBJ2‐1   28,982    N5‐CD8       5.52497984
  TRBV12‐3   TRBJ1‐1   24,064    N3‐CD8       5.10780647
  TRBV30     TRBJ1‐2   45,654    M1‐CD4       13.9589493
  TRBV12‐3   TRBJ2‐2   33,833    M1‐CD4       10.3446167
  TRBV12‐3   TRBJ1‐1   24,993    M1‐CD4       7.64174048
  TRBV6‐5    TRBJ2‐7   44,913    M6‐CD4       5.96502506
  TRBV20‐1   TRBJ2‐1   39,180    M3‐CD4       5.80612177
  TRBV30     TRBJ1‐1   17,997    M1‐CD4       5.50267689
  TRBV30     TRBJ1‐1   281,888   M7‐CD8       40.7552844
  TRBV6‐5    TRBJ2‐2   177,317   M8‐CD8       24.3322982
  TRBV6‐5    TRBJ2‐7   68,199    M5‐CD8       21.2365324
  TRBV12‐3   TRBJ2‐1   132,063   M7‐CD8       19.0936298
  TRBV30     TRBJ2‐5   73,658    M6‐CD8       18.0772686
  TRBV6‐1    TRBJ2‐7   55,800    M9‐CD8       15.5356889
  TRBV4‐3    TRBJ2‐5   39,717    M3‐CD8       8.19887701
  TRBV30     TRBJ2‐7   39,449    M3‐CD8       8.14355312
  TRBV12‐3   TRBJ1‐6   38,230    M3‐CD8       7.89191198
  TRBV6‐2    TRBJ2‐7   31,203    M2‐CD8       7.41900509
  TRBV12‐3   TRBJ2‐5   43,944    M4‐CD8       7.05995759
  TRBV6‐2    TRBJ2‐2   22,112    M5‐CD8       6.88547051
  TRBV30     TRBJ2‐2   15,645    M1‐CD8       6.6954542
  TRBV12‐3   TRBJ2‐5   27,212    M6‐CD8       6.67841418
  TRBV6‐2    TRBJ2‐5   27,203    M6‐CD8       6.67620539
  TRBV30     TRBJ1‐4   15,233    M1‐CD8       6.51913415
  TRBV12‐3   TRBJ2‐2   30,744    M3‐CD8       6.34655877
  TRBV12‐3   TRBJ2‐2   38,148    M4‐CD8       6.1287835
  TRBV5‐1    TRBJ2‐1   24,851    M2‐CD8       5.90871697
  TRBV2      TRBJ2‐5   12,950    M1‐CD8       5.54209855
  TRBV5‐8    TRBJ1‐6   16,347    M5‐CD8       5.09030329
  TRBV12‐3   TRBJ2‐7   27,534    M4‐Tissue    32.4996164
  TRBV4‐3    TRBJ1‐2   73,434    M5‐Tissue    24.0886472
  TRBV4‐1    TRBJ2‐6   54,498    M5‐Tissue    17.8770473
  TRBV20‐1   TRBJ1‐4   27,013    M2‐Tissue    17.5660034
  TRBV5‐1    TRBJ2‐7   13,014    M7‐Tissue    17.2405114
  TRBV30     TRBJ1‐1   70,700    M1‐Tissue    16.0120668
  TRBV4‐3    TRBJ1‐2   6,465     M6‐Tissue    14.0107925
  TRBV20‐1   TRBJ2‐6   9,564     M7‐Tissue    12.6700669
  TRBV20‐1   TRBJ2‐7   9,212     M7‐Tissue    12.2037491
  TRBV5‐1    TRBJ1‐2   39,469    M3‐Tissue    11.3619419
  TRBV6‐5    TRBJ1‐1   16,242    M2‐Tissue    10.5618416
  TRBV4‐1    TRBJ2‐6   4,634     M6‐Tissue    10.0426934
  TRBV5‐1    TRBJ1‐2   8,463     M4‐Tissue    9.98925886
  TRBV12‐3   TRBJ1‐1   38,671    M9‐Tissue    8.83609659
  TRBV30     TRBJ2‐7   29,333    M3‐Tissue    8.44409132
  TRBV12‐3   TRBJ2‐2   22,954    M5‐Tissue    7.52962942
  TRBV30     TRBJ2‐1   25,885    M3‐Tissue    7.45151549
  TRBV12‐3   TRBJ2‐2   25,845    M3‐Tissue    7.44000069
  TRBV5‐1    TRBJ2‐1   11,003    M2‐Tissue    7.15502666
  TRBV30     TRBJ1‐6   30,986    M1‐Tissue    7.01767895
  TRBV30     TRBJ1‐1   285       M8‐Tissue    7.00417793
  TRBV30     TRBJ2‐7   285       M8‐Tissue    7.00417793
  TRBV12‐3   TRBJ2‐7   29,615    M9‐Tissue    6.76685373
  TRBV12‐3   TRBJ2‐7   19,908    M5‐Tissue    6.53044622
  TRBV12‐3   TRBJ2‐7   4,895     M7‐Tissue    6.48473207
  TRBV30     TRBJ2‐7   27,923    M9‐Tissue    6.38024166
  TRBV30     TRBJ1‐4   26,309    M9‐Tissue    6.01145213
  TRBV5‐1    TRBJ2‐7   2,719     M6‐Tissue    5.89255142
  TRBV14     TRBJ2‐3   8,461     M2‐Tissue    5.50201587
  TRBV20‐1   TRBJ1‐1   2,425     M6‐Tissue    5.25540169
  TRBV5‐1    TRBJ2‐1   4,310     M4‐Tissue    5.08728651
  TRBV11‐3   TRBJ2‐2   22,117    M1‐Tissue    5.00903651
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In order to examine the potential contribution of specific TRBV/TRBJ combinations to disease progress, comparison of the relative frequencies of TRBV/TRBJ combinations between patients and controls was performed. There were 46 up‐regulated and 10 down‐regulated TRBV/TRBJ combinations as has been found after comparison between CD4 group of patients and controls. There were 12 up‐regulated combinations and 12 down‐regulated combinations as has been found after comparison between CD8 group of patients and controls (Figure [12](#mgg3792-fig-0012){ref-type="fig"}). We then compared different TRBV/TRBJ combinations in CD4, CD8, tissue group of patients as shown in Figure [13](#mgg3792-fig-0013){ref-type="fig"}.

![TRBV/TRBJ combination in groups. (a) Comparison between CD4^+^ cell group in patients and CD4^+^ cell group in controls. (b) Comparison between CD8^+^ cell group in patients and CD8^+^ cell group in controls](MGG3-7-e00792-g012){#mgg3792-fig-0012}

![TRBV/TRBJ combination in groups. (a) Comparison between CD8^+^ cell group in patients and CD4^+^ cell group in patients. (b) Comparison between tissue group in patients and CD4^+^ cell group in patients. (c) Comparison between CD8^+^ cell group in patients and tissue group in patients](MGG3-7-e00792-g013){#mgg3792-fig-0013}

4. DISCUSSION {#mgg3792-sec-0018}
=============

Tuberculosis, a well‐known infectious disease, is closely related to immune reaction in its development, diagnosis and treatment process (Janis, Kaufmann, Schwartz, & Pardoll, [1989](#mgg3792-bib-0007){ref-type="ref"}; Cooper, [2009](#mgg3792-bib-0005){ref-type="ref"}; Andersen et al., [2000](#mgg3792-bib-0001){ref-type="ref"}; MacMicking, Taylor, & McKinney, [2003](#mgg3792-bib-0012){ref-type="ref"}). The immune repertoire is characterized by a complex and dynamic organization, a highly organized, dynamic and coherent structure to assist in the understanding of the generation and selection of immune TCRs. Thus, fully measuring the diversity of the T cell repertoire, which determines the flexibility and specificity in the cellular immune response, could provide new insights into the underlying disease process (Burgos, [1996](#mgg3792-bib-0002){ref-type="ref"}; Liu et al., [2017](#mgg3792-bib-0011){ref-type="ref"}). In 1996, Li, et al., investigated disease‐specific change in gamma‐delta T cell repertoire of pulmonary tuberculosis patients by flow cytometric analysis of blood and bronchoalveolar lavage gamma‐delta T cells (Li et al., [1996](#mgg3792-bib-0008){ref-type="ref"}). They demonstrated the hypothesis that gamma‐delta T cells play a role in the protective immune response to Mtb infection (Li et al., [1996](#mgg3792-bib-0008){ref-type="ref"}). In 2018, Chaofei Cheng, et al., found that the CDR3δ tended to be more polyclonal and CDR3γ tended to be longer in TB patients; the γδ T cells expressing CDR3 sequences using a Vγ9‐JγP rearrangement expanded significantly during Mtb infection by NGS study of repertoire (Cheng et al., [2018](#mgg3792-bib-0004){ref-type="ref"}).

However, for further understanding of immune reaction, repertoire diversity and stability within tuberculosis patients and controls still needs more comprehensive studies. Here, we present a study of enormous characterization data of tuberculosis patients and comparable controls. HEC number, HEC ratio, Shannon entropy and Gini coefficient were applied to evaluate the general characteristics of the repertoires. In both patients and normal controls, the HEC number and HEC ratio showed higher frequency in tissue samples than in CD8 or CD4 samples. Besides, HEC number and HEC ratio showed higher frequency in CD8 than CD4 samples in both patients and normal controls. This suggested that a more centralized and stronger immune reaction in tissue samples than in the CD4^+^ or CD8^+^ cell samples provides potential evidence for further elucidation for the understanding of the mechanism in depth. The Shannon entropy which was previously used as an economy parameter, was introduced in this study to illustrate the multiplex of the immune system. According to the criteria, we found that the tissue group\'s repertoire showed lowest complexity in patients which also suggests the strong immune reaction in tuberculosis tissue than other sample type groups.

The length distribution of CDR3 in each sample was fitted to Gaussian distribution, which provides an evenly distributed data set. Consistent with the previous study, we found that there were significant differences between patients and control groups. Since, the CDR3 sequence which was commonly expressed in patient samples could provide a solid clue for disease‐specific immune reaction research, we evaluated all amino acids shared in all samples. The CD4, CD8 groups showed similar sharing of sequences which were quite different to that of tissue groups. In the analysis of TRBV and TRBJ gene usage, we found significant difference between CD4, CD8 and tissue groups of patients. These differently expressed genes showed a disease‐specific gene expression profile which provides further information for tuberculosis and control study. To find further disease‐specific CDR3 sequences, we also investigated the TRBV/TRBJ combination in patients and controls. Within same group analysis, we found highly expressed combination sequences in each certain group. And we also found differential expression level of recombination sequences in the comparison between patients' samples and normal control samples, which revealed the important function of TRBV/TRBJ combination in the immune of tuberculosis and provide presupposition for further study of diagnosis or treatment application.

In conclusion, our study first elucidated the immune repertoire characteristics of tuberculosis patients using NGS based methods. We found that the CDR3 sequences were extremely highly expressed in tuberculosis patients' tissue samples than other type of samples, which suggested a specific and strong immune reaction during the development of tuberculosis. We then analyzed the CDR3 sequence sharing in all samples and each group. Later, we elucidated the TRBV, TRBJ usage and TRBV/TRBJ combination in all samples. This study provides a whole spectrum and profile of tuberculosis patients and studied the specific recombination CRD3 sequences which differ between the patients and controls. Although the sample number is relatively small, we still provide a useful resource of further study on the diagnosis, prognosis and prevention of tuberculosis by understanding candidates' immunology repertoire features.
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